Last reviewed · How we verify
Levofloxacin 0.5%
At a glance
| Generic name | Levofloxacin 0.5% |
|---|---|
| Also known as | Tavanic |
| Sponsor | Indiana University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis (PHASE2)
- Bronchoscopic Levofloxacin, Gentamicin, or Sham for Acute Exacerbation of Bronchiectasis (PHASE4)
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults (PHASE2)
- VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (NA)
- Helicobacter Pylori Eradication and Follow-up (PHASE4)
- Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients (PHASE4)
- Effects of CKI for Oral Mucositis Caused by Radiotherapy for Head and Neck Cancer (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levofloxacin 0.5% CI brief — competitive landscape report
- Levofloxacin 0.5% updates RSS · CI watch RSS
- Indiana University School of Medicine portfolio CI